Metabolic Manipulation in Chronic Heart Failure

Overview

Conventional measures used for the treatment of chronic heart failure act predominantly by reducing the work performed by the heart. In a recent study, the investigators showed that one drug (perhexiline) substantially improved symptoms and cardiac function in heart failure. The investigators wish to confirm these findings and test whether or not this drug acts by altering the heart's energy source thus augmenting the energetic status and work efficiency of the heart.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: September 2011

Detailed Description

Perhexiline maleate is an antianginal agent which increases the efficiency of energy production by shifting substrate utilisation from free fatty acids towards glucose. We showed that perhexiline therapy was highly effective in improving exercise capacity, symptoms and cardiac function in patients with systolic heart failure of both ischaemic and non ischaemic aetiology. Perhexiline acts by inhibiting both carnitine palmitoyl transferase-1 (CPT-1) and CPT-2, which are key enzymes in mitochondrial free fatty acid uptake. This leads to increased myocardial glucose substrate utilization. Further we wish to ascertain whether or not this drug improves cardiac energetics and efficiency by altering substrate utilization. In this proposal we will assess the cardiac function (by cardiac Magnetic Resonance Imaging MRI), cardiac energetic status (by cardiac Magnetic Resonance Spectroscopy MRS), cardiac efficiency (via pressure-volume loops) and substrate utilization (via left and right heart catheterization), following one month of perhexiline therapy or placebo in patients with symptomatic idiopathic dilated cardiomyopathy on optimal conventional heart failure medications. An interim analysis is planned after 20 patients.

Interventions

  • Drug: Perhexiline
    • 100mg o bd
  • Drug: Placebo
    • 1 tablet bd

Arms, Groups and Cohorts

  • Experimental: Perhexiline
    • perhexiline 100mg bd for 1 month duration
  • Placebo Comparator: Placebo
    • placebo one tablet bd for 1 month duration

Clinical Trial Outcome Measures

Primary Measures

  • Change in cardiac energetics as demonstrated by resting myocardial PCr/ATP ratio from cardiac MRS
    • Time Frame: 1 Month

Secondary Measures

  • Change in mechanical efficiency (external work / MVO2)
    • Time Frame: 1 Month
  • Change in respiratory quotient
    • Time Frame: 1 Month

Participating in This Clinical Trial

Inclusion Criteria

  • Optimally-medicated idiopathic dilated cardiomyopathy – Symptomatic ( NYHA IIb-III) – Impaired left ventricular systolic function (EF < 40%) Exclusion Criteria:

  • Abnormal liver function tests (defined as above twice the upper limit of normal (ULN)) – Concomitant use of Amiodarone , Quinidine , Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme. – Pre-existing evidence of peripheral neuropathy. – Women of childbearing potential. – Patients with implantable cardiac devices (or any other contraindication to MRI). – Obesity ( BMI > 32) – Obstructive sleep apnea syndrome – Patients with known hypersensitivity to perhexiline – Patients with impaired renal function (Creatinine > 250 µmol/L) – Valvular heart disease defined as more than moderate valvular stenosis or regurgitation. – Atrial Fibrillation

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital Birmingham NHS Foundation Trust
  • Collaborator
    • British Heart Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Roger Beadle, Research Fellow to Professor MP Frenneaux – University Hospital Birmingham NHS Foundation Trust
  • Overall Official(s)
    • Michael P Frenneaux, MBBS MD, Principal Investigator, University of Birmingham
    • Roger M Beadle, MBBS, Study Director, University of Birmingham

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.